Phase 3RecruitingAge-related condition
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- Sponsor
- Anthos Therapeutics, Inc. (Industry)
- Enrollment
- 2,500 planned
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- Abelacimab; Placebo
- Ages
- older adults
- Registry
- NCT05712200, CTIS2023-503224-66-00
Full record on ClinicalTrials.gov
From the registry
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
Primary outcomes
- Efficacy: Time to first event of ischemic stroke or systemic embolism (SE)
- Safety: Time to first occurrence of Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding
History
Primary completion expected
Last registry update
Registered
Started